Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure - EMPHASIS-HF


Based on earlier trials, current guidelines indicate that the use of mineralocorticoid receptor antagonists such as spironolactone and eplerenone in addition to standard therapy in patients with left ventricular (LV) systolic dysfunction post-myocardial infarction (MI) and New York Heart Association (NYHA) class III or IV symptoms is a class I indication. The current trial sought to study the utility of eplerenone in patients with LV systolic failure and mild (NYHA class II) symptoms.